Trial Profile
A Phase I/II Trial of Dasatinib in Combination With Trastuzumab and Paclitaxel in the First Line Treatment of Her2-Positive Metastatic Breast Cancer (MBC) Patients
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Paclitaxel; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 01 Apr 2019 Status changed from active, no longer recruiting to completed, according to the results published in the Breast Cancer Research and Treatment
- 08 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress